Table 1 Subjects demonstration
From: Chronic cough and obstructive sleep apnoea in a sleep laboratory-based pulmonary practice
Characteristics | OSA nā=ā99 | Non-OSA nā=ā32 | p-value |
|---|---|---|---|
Age | 52.2Ā±11.6 | 48.3Ā±13.1 | 0.105 |
Male, n (%) | 75 (75.8) | 17 (53.1) | 0.025 |
BMI | 28.9Ā±4.1 | 24.9Ā±4.3 | 0.000 |
Epworth Sleepiness Scale | 12.9Ā±4.5 | 12.8Ā±5.5 | 0.884 |
Total AHI, /h | 53.6Ā±24.7 | 10.1Ā±4.3 | 0.000 |
Pulmonary function test | Ā | Ā | Ā |
FEV1/FVC | 83.7Ā±8.4 | 82Ā±12.5 | 0.394 |
FEV1 (% predicted) | 82.6Ā±20.1 | 82.6Ā±17.5 | 0.993 |
FVC (% predicted) | 82.4Ā±17.9 | 86.8Ā±22.3 | 0.278 |
Chronic cough | 39 (39.4) | 4 (12.5) | 0.005 |
Upper airway cough syndrome | 79 (79.8) | 23 (71.9) | 0.340 |
Gastro-esophageal reflux disease | 43 (43.4) | 5 (15.6) | 0.006 |
Asthma | 18 (18.2) | 5 (15.6) | 1.000 |
Medication | Ā | Ā | Ā |
Nasal steroid | 72 (72.7) | 20 (62.5) | 0.276 |
Anti-histamine | 79 (79.8) | 23 (71.9) | 0.340 |
ACEI or ARB | 11 (11.1) | 0 (0.0) | 0.065 |
Inhaled corticosteroid | 18 (18.2) | 5 (15.6) | 1.000 |
Long-acting Ī²2 agonist | 4 (4.0) | 2 (6.2) | 0.634 |
Proton pump inhibitor | 43 (43.4) | 5 (15.6) | 0.006 |